Home Health EDGC, developed head and neck cancer tracking technology using liquid biopsy

EDGC, developed head and neck cancer tracking technology using liquid biopsy

by news dir

Global genome company Ewon Diagnomics (hereinafter referred to as EDGC) has developed a technology to detect and track the progress of head and neck cancer using cell-free DNA liquid biopsy technology in collaboration with Kangdong Kyunghee University Hospital and published in the international journal’Oral Diseases’. It was revealed on the 29th.
Cell-free DNA liquid biopsy technology is a diagnostic method that analyzes DNA floating in body fluids such as blood to diagnose cancer early and track progression. EDGC achieved the feat of expanding the area to lung cancer, breast cancer, colon cancer, stomach cancer, and even head and neck cancer.
The joint research paper released this time is of great value in that it has been recognized by international journals for its possibility to analyze ctDNA (cancer cell-derived DNA) present in saliva and use it for diagnosis of head and neck cancer, the company explained. The research team has confirmed the potential as a new tool that can accurately track the treatment effects of cancer patients using this technology.
EDGC is taking the lead in the development of technology for early cancer diagnosis and residual cancer testing in Asia using blood as a sample, and has recently reached the completion stage. The recently announced follow-up test for residual cancer has the advantage of being able to detect even a very small amount of cancer genomes because it tracks and analyzes genetic variations that occur specifically in each patient. In addition, for early diagnosis of cancer, cancer can be accurately analyzed even in the early stages by measuring various pattern analysis existing in cancer cells with a multi-omics technique and developing and determining artificial intelligence (AI) algorithms to analyze them.
Seong-Hoon Lee, CTO of EDGC, said, “We are conducting research and development with the aim of applying all cancers to early cancer diagnosis and follow-up monitoring using cfDNA liquid biopsy technology in the blood. In order to diagnose cancer in the very early stages, it is necessary to be able to detect a very small amount (~0.01%) of cfDNA, which is about one in full bloom. Said.
[김경택 기자 [email protected]]

[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]

Copyright ⓒ MBN (daily broadcasting) Unauthorized reproduction and redistribution prohibited

<!– 타불라 2018-03-06

타불라 2018-03-06 –>

  • Popular Videos
  • Attention


Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.